Successful Scientific Advisory Board Meeting in Oxford

We recently hosted a focused Scientific Advisory Board (SAB) meeting in Oxford, reflecting the significant progress in our development of OsteoSight. A subsection of our SAB, including Felicia Cosman, Kassim Javaid, Robert Pignolo, and Tim Briggs, attended the meeting, bringing their vast experience across geriatrics, osteoporotic care, and leading fracture liaison services with them. The agenda focused on updating the board on our recent progress, seeking guidance for upcoming regulatory interactions, and strategizing future steps for OsteoSight's market deployment.

?

Why host a SAB now?

The timing of this SAB meeting aligns with our product and regulatory goals over the next 12 months. We have achieved technical excellence and are now setting our sights on clinical deployment, and the expertise of our board members is crucial in guiding this next phase.

Why this team?

Felicia, Kassim, Robert, and Tim were chosen for their unique expertise:

Felicia Cosman: A hugely experienced leader in developing and deploying treatments for osteoporosis, providing critical insights into treatment integration.

Kassim Javaid: A leading figure in fracture liaison services (FLS), offering downstream implementation understanding and strategies.

Robert Pignolo: A practicing gerontologist at the Mayo Clinic, ensuring our technology meets practical clinical needs.

Tim Briggs: A senior physician with a wealth of experience in orthopedics, delivering optimal care pathways, and nation-wide service improvement.

?

Discussion and decisions:

Tim acted as chair for the meeting, ensuring the efficient?coverage of all the agenda points.?The SAB members shared the lessons they have learned from administering similar programs. They particularly emphasized the need to bring osteoporosis to the forefront of healthcare priorities. The group highlighted the challenge of getting health systems to prioritize osteoporosis in patients with multiple comorbidities and the necessity of pre-fracture interventions to improve outcomes.

One key takeaway was the need to focus on the stakeholders who are responsible for the actual implementation of technologies and systems such as OsteoSight. Additionally, the importance of demonstrating efficiency for some stakeholders was stressed.

?

Impact on future plans:

These discussions will now shape the downstream development of our flagship product, OsteoSight, and our wider product suite. Key themes will center around workflow optimization, monitoring, and integrations.

?

Next steps:

Our next in-person SAB is scheduled for June 2025, with an interim virtual meeting set to be held around the time we approach our key regulatory milestone later this year.

The SAB meeting was a resounding success, providing helpful guidance and support for the subsequent phases of OsteoSight's development and deployment. We look forward to continuing to collaborate with our esteemed SAB members as we work towards improving outcomes for people with osteoporosis worldwide.